Spironolactone inhibits NADPH oxidase-induced oxidative stress and enhances eNOS in human endothelial cells.
about
Drug Targets for Oxidative Podocyte Injury in Diabetic NephropathyAcute effect of mineralocorticoid receptor antagonism on vascular function in healthy older adultsCellular death, reactive oxygen species (ROS) and diabetic complications.Spironolactone Protects against Diabetic Cardiomyopathy in Streptozotocin-Induced Diabetic Rats
P2860
Spironolactone inhibits NADPH oxidase-induced oxidative stress and enhances eNOS in human endothelial cells.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Spironolactone inhibits NADPH ...... OS in human endothelial cells.
@en
Spironolactone inhibits NADPH ...... OS in human endothelial cells.
@nl
type
label
Spironolactone inhibits NADPH ...... OS in human endothelial cells.
@en
Spironolactone inhibits NADPH ...... OS in human endothelial cells.
@nl
prefLabel
Spironolactone inhibits NADPH ...... OS in human endothelial cells.
@en
Spironolactone inhibits NADPH ...... OS in human endothelial cells.
@nl
P2860
P1476
Spironolactone inhibits NADPH ...... OS in human endothelial cells.
@en
P2093
Ashraf Taye
Henning Morawietz
P2860
P304
P577
2011-01-01T00:00:00Z